Acetyl-l-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network

PURPOSE: Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN). We incorporated acetyl-l-carnitine (ALCAR) to prevent PN and allow for adequa...

Descripción completa

Detalles Bibliográficos
Autores principales: Callander, Natalie, Markovina, Stephanie, Eickhoff, Jens, Hutson, Paul, Campbell, Toby, Hematti, Peiman, Go, Ronald, Hegeman, Robert, Longo, Walter, Williams, Eliot, Asimakopoulos, Fotis, Miyamoto, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2014
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175433/
https://www.ncbi.nlm.nih.gov/pubmed/25168296
http://dx.doi.org/10.1007/s00280-014-2550-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175433/
https://www.ncbi.nlm.nih.gov/pubmed/25168296
http://dx.doi.org/10.1007/s00280-014-2550-5

Ejemplares similares